Cadila Healthcare is currently trading at Rs. 358.35, up by 8.30 points or 2.37% from its previous closing of Rs. 350.05 on the BSE.
The scrip opened at Rs. 352.00 and has touched a high and low of Rs. 360.00 and Rs. 342.00 respectively. So far 57163 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 554.20 on 25-Jul-2017 and a 52 week low of Rs. 341.65 on 22-May-2018.
Last one week high and low of the scrip stood at Rs. 383.53 and Rs. 342.00 respectively. The current market cap of the company is Rs. 36578.32 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.38% and 7.84% respectively.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Clindamycin Phosphate Topical Solution USP (Cleocin T), 1%. Clindamycin is an antibiotic which works by stopping the growth of bacteria. It is used to treat acne and helps to decrease the number of acne lesions. It will be manufactured at group's Topical manufacturing facility at Ahmedabad.
In line with this, the group now has 204 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
